The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence.

MLA

Gui, Huan, et al. “The Combination of a PTP1B Inhibitor, TNFR2 Blocker, and PD‑1 Antibody Suppresses the Progression of Non‑small Cell Lung Cancer Tumors by Enhancing Immunocompetence.” Oncology Reports, vol. 52, no. 5, Nov. 2024. EBSCOhost, https://doi.org/10.3892/or.2024.8808.

APA

Gui, H., Nie, Y., Yuan, H., Jing, Q., Li, L., Zhu, L., Chen, S., Wang, M., Wan, Q., Lv, H., Nie, Y., & Zhang, X. (2024). The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‑1 antibody suppresses the progression of non‑small cell lung cancer tumors by enhancing immunocompetence. Oncology Reports, 52(5). https://doi.org/10.3892/or.2024.8808

Chicago

Gui, Huan, Yujie Nie, Haohua Yuan, Qianyu Jing, Linzhao Li, Lan Zhu, Shuanghui Chen, et al. 2024. “The Combination of a PTP1B Inhibitor, TNFR2 Blocker, and PD‑1 Antibody Suppresses the Progression of Non‑small Cell Lung Cancer Tumors by Enhancing Immunocompetence.” Oncology Reports 52 (5). doi:10.3892/or.2024.8808.